25 September 2025

Cost-utility analysis of recombinant human erythropoietin in cancer patients with anemia induced by chemotherapy in Thailand (in Thai language)

View Count

Share this research

Project Code 01-314-2550

Country

Thailand

Project Duration

Start : 1 January 2007

Research Status

Completed 100%

Complete Research Report

Quantity 0 files

Download Count

0 times

All research

25 September 2025

Cost-utility analysis of recombinant human erythropoietin in cancer patients with anemia induced by chemotherapy in Thailand (in Thai language)

About Project

Content

An increase in the number of cancer patients with anemia has been observed in Thailand due to an increase of cancer patients and the use of chemotherapy for treatment of cancers that cause bone marrow suppression. Although blood transfusion is an effective way of increasing the hemoglobin level in anemic patients, several limitations do exist with this approach. These limitations include: a severe shortage of blood donations and the high cost of screening of blood donations. As a result, an innovative recombinant human erythropoietin (rHuEPO ) has been considered as an alternative choice for the treatment of anemia caused by chemotherapy. However, a cost-utility analysis on rHuEPO for treating anemic cancer patients induced by chemotherapy compared to blood transfusion alone found that it is not cost-effective under the Thai health care setting.

Research Type

Others

Related Technologies

Health Policies

Pharmaceuticals

Others

Funding Source

Thai Health Promotion Foundation (ThaiHealth)

Keyword / Search / TAG